Dr. Amy M. Schell, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
1720 Nicholasville Rd, Suite 701
Lexington, KY 40503
Who else practices at this address →
Fayette County includes mental health (15% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Kentucky College of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 350
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: University of Kentucky College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
KY license 46229
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Health Lexington Lexington, KY
- Baptist Health Corbin Corbin, KY
- Baptist Health Richmond Richmond, KY
Medical groups
- Baptist Health Medical Group Inc (2,472 clinicians)
- H2 Rehabilitation Services of Kentucky, LLC (182 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 350
- Services billed
- 825
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 312 | 188 |
| Established patient office or other outpatient visit, 40-54 minutes | 101 | 62 |
| Established patient office or other outpatient visit, 20-29 minutes | 73 | 68 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 73 | 25 |
| New patient office or other outpatient visit, 60-74 minutes | 61 | 61 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 24 | 22 |
| New patient office or other outpatient visit, 45-59 minutes | 20 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Lexington, KY | 749 |
| Ondansetron Hcl Other prescribers in Lexington, KY | 102 |
| Dexamethasone Other prescribers in Lexington, KY | 87 |
| Tamoxifen Citrate Other prescribers in Lexington, KY | 84 |
| Revlimid (lenalidomide) | 58 |
| Exemestane | 55 |
| Eliquis (apixaban) Other prescribers in Lexington, KY | 53 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Lexington, KY | 50 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Lexington, KY | 48 |
| Lenalidomide | 46 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $70.29 in total to this clinician.
| Iovance Biotherapeutics, Inc. | $33.57 |
|---|---|
| Daiichi Sankyo Inc. | $24.30 |
| Gilead Sciences, Inc. | $12.42 |
| Food and Beverage | $57.87 |
|---|---|
| Education | $12.42 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Dec 22, 2025 | Education Trodelvy · ONC · in-kind Company’s description;4267134;G360;11104958 | $12.42 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 3 companies. The companies reported $198,112 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
AstraZeneca Pharmaceuticals LP - A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in…
AstraZeneca Pharmaceuticals LP - INAVO123
Genentech, Inc. - Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients
Genentech, Inc. - TOL2506A-EXT
Tolmar, Inc. - TOL2506A
Tolmar, Inc. - A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurren…
AstraZeneca Pharmaceuticals LP - SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negativ…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.